UK universities launch 4D medical device manufacturing project
Researchers from the UK's University of Birmingham and Imperial College London have launched a new 4D medical device manufacturing project.
The 4D Health Tech initiative seeks to fill a crucial gap in traditional medical device manufacturing design processes by incorporating factors such as growth, movement, and tissue regeneration or degeneration, which are often overlooked.
The project will promote the use of materials that degrade predictably and promote faster healing, and combine this ethos with automated design, advanced manufacturing processes, and patient specific pre-clinical testing – which is expected to result in 'better' medical devices that cater to more diverse patient populations.
Backed by £1.2m in funding from the UK Research and Innovation's (UKRI) Engineering and Physical Sciences Research Council (EPSRC), the three-year project will create Network Plus, an initiative intended to connect academics, businesses, clinicians, patients, and policymakers, serving as a conduit towards the creation of bigger, longer-term research projects in the field.
The project funding is part of a broader £10m package allocated by EPSRC across the UK's manufacturing sector to respond to Tomorrow's Engineering Research Challenges, a paper the UKRI published in 2022. Concerning medical device and equipment manufacturing, the paper highlights the importance of a re-manufacturing and re-use approach to ensure sustainability in manufacturing for the sector to support a move towards the principles of a circular economy.
According to Dr Sophie Cox, associate professor in healthcare technologies at Birmingham University's School of Chemical Engineering, medical devices designed to replace or repair our bodies typically neglect the dimension of time, a reality that compromises their function and lifespan.
'Our vision is to transform the way we engineer medical devices,' said Dr Cox.
'Fostering connections across the supply chain will create a new culture of 4D Health Tech embedding innovative thinking, patient perspective and diversity – ensuring this new age of medical devices offers improved healthcare outcomes for everyone.'
In related manufacturing developments in the medical device sector, companies are ramping up their investment in 3D printing for the creation of custom prosthetics, implants and surgical tools that meet the individual needs of patients. According to GlobalData analysis, the medical 3D printing market is growing at a CAGR of 21% and forecast to reach a valuation of $4bn in 2026, up from $2bn in 2022.
"UK universities launch 4D medical device manufacturing project" was originally created and published by Medical Device Network, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Avicenna.ai scoops CE marks for two AI fracture detection tools
French artificial intelligence (AI)-based medical imaging company has secured CE marks for a pair of radiologic screening tools to detect fractures from CT scans. CINA-VCF Quantix is an AI algorithm is used to detect unsuspected vertebral compression fractures (VCFs) in patients undergoing CT scans for unrelated conditions, while CINA-CSpine is designed for the detection and triage of cervical spine fractures. Both tools gained 510(k) clearance from the US Food and Drug Administration (FDA) in 2024, while the tools' receipt of CE mark follows clearance on five other AI tools in 2024 under the EU's Medical Device Regulation (EU MDR). For use in patients aged 50 and above who are undergoing patients undergoing CT scans of the chest or abdomen for other conditions, CINA-VCF Quantix automatically labels vertebrae and calculates vertebral height loss ratios in the thoracic and lumbar spine. In cases where a vertebral height loss ratio exceeds 20%–25%, a figure indicative of a moderate- to severe VCF, the algorithm generates prompts notifying radiologists to report their early findings in support of proactive patient care, Avicenna stated. co-founder and CEO, Cyril Di Grandi commented: "Osteoporotic vertebral fractures can have a profound impact on patients' quality of life. "By encouraging the reporting of VCF presence and severity, CINA-VCF Quantix has the potential to make a real difference in long-term patient outcomes." CINA-CSpine is designed to automatically flag suspected acute cervical spine fractures through radiologists' existing systems. Di Grandi continued: "The launch of CINA-CSpine in the European market marks a significant step forward in trauma care. By reducing the time between scan and diagnosis, we're helping radiologists catch cervical spine fractures faster and more reliably.' A 2023 report on AI in healthcare by GlobalData forecasts that global revenue for AI platforms across the sector will reach a valuation of almost $19bn by 2027, with the radiology field seeing some of the highest implementation of AI technologies. Research indicates that thoracolumbar fusion procedures, one of the most common spine surgery types, are in growing demand, with thoracolumbar procedures such as anterior lumbar interbody fusion (ALIF) and posterior lumbar fusion (PLF) in the US projected to see respective rises from 46,903 to 55,528 and 248,416 to 297,994 between 2020 and 2040. According to GlobalData, the spinal fusion market segment, of which thoracolumbar fusion is a part, is growing at a CAGR of 2.3% and forecast to reach a valuation of around $11.23bn by 2033. " scoops CE marks for two AI fracture detection tools" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
Yahoo
2 days ago
- Yahoo
Intravascular lithotripsy: market competition and clinical potential: new issue of Medical Technology out now
The field of Intravascular lithotripsy (IVL), a medical procedure that uses ultrasound shockwaves to break down calcified plaque in arteries, particularly those in the coronary arteries or peripheral arteries, is generating increasing levels of interest. This month's cover feature looks at the clinical promise IVL holds beyond the financial buzz it has generated in recent times. This issue also features analyst comment on the impact Trump's tariffs are having on the medical device industry, with companies moving to stockpile equipment in certain areas. Don't miss our two interviews out of Biomed 2025, which recently took place in Tel Aviv, Israel in May, with each featuring insight into how the bioconvergence and neuromodulation markets are continuing to develop globally. All this and the latest medtech industry news, comment, and analysis from GlobalData. If you like our magazine, sign up to have each issue delivered to your inbox. "Intravascular lithotripsy: market competition and clinical potential: new issue of Medical Technology out now" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
2 days ago
- Yahoo
‘Dupixent-fuelled' atopic dermatitis market sales to hit $22.4bn by 2033
The global atopic dermatitis (AD) market is poised to reach $22.4bn in drug sales within the decade, buoyed by the availability of targeted therapies, market analysis suggests. A 2025 report published by GlobalData, which analysed the seven major markets of the US, UK, France, Germany, Italy, Spain, and Japan, forecasts sector sales will reach the $22.4bn figure by 2033, up from $8.5bn in 2023, reflecting a compound annual growth rate (CAGR) of 10.2%. While not as fast-growing as the weight loss market in the metabolic disease space, the AD market growth is salient given the market's size compared to other dermatology indications. GlobalData healthcare analyst, Filippos Maniatis, comments: 'AD is a growing market with an impressive pipeline of new products from current and future players in the field. The AD space was previously dominated by broad-acting immunomodulatory agents, which are now being slowly replaced by more targeted agents. This shift is likely due to better comprehension of the pathophysiology behind AD and the approval of several new systemic agents.' GlobalData is the parent company of Pharmaceutical Technology. One of those targeted agents that has taken the market by storm is Regeneron and Sanofi's jointly developed Dupixent (dupilumab), first approved in the US in 2017. The blockbuster monoclonal antibody has seen its sales increase year-over-year amid high uptake from AD – reaching $14.9bn in sales in 2024. Dupixent is approved for a range of diseases, including a lucrative asthma indication. The report says that the gap of unmet need in AD, which is closing courtesy of Sanofi and Regeneron, is set to shrink even further depending on future approvals for more targeted therapies. One modality poised as a future disruptor is the OX40 inhibitor class of drugs that work by inhibiting T-cell activation and inflammation via the OX40 receptor on the immune cells. Pipeline candidates in development include Amgen and Kyowa Kirin's rocatinlimab, Sanofi's amlitelimab, and Astria Therapeutics' telazrolimab. Another class with a potential future in AD is interleukin (IL) inhibitors. LEO Pharma, GSK, and Nektar all have assets in clinical development. Maniatis concludes: 'With multiple pipeline agents in development, key unmet needs may be further addressed. Such unmet needs include the lack of personalised treatments through improved diagnostic methods, the high cost of current therapy options, the limited therapeutic options for chronic hand eczema, and better long-term disease control and management.' "'Dupixent-fuelled' atopic dermatitis market sales to hit $22.4bn by 2033" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
